Being close enough to patients to care is as critical as remaining distant enough from a pathogen to be safe. This strategy simultaneously frustrates and supports public trust.
AMA J Ethics. 2020;22(1):E22-27. doi:
10.1001/amajethics.2020.22.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
As larger organizations become more influential in the health care sector, the Code can help physicians navigate those organizations’ influence on their practices.
AMA J Ethics. 2020;22(3):E217-220. doi:
10.1001/amajethics.2020.217.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Corporatization in health care has complicated clinicians’ and organizations’ efforts to balance interests of individual patients against an organization’s bottom line.
AMA J Ethics. 2020;22(3):E187-192. doi:
10.1001/amajethics.2020.187.
Health system function, resilience, and sustainability are needed to help prepare trainees to lead, innovate, and prioritize a circular supply chain with low emissions.
AMA J Ethics. 2022;24(10):E951-958. doi:
10.1001/amajethics.2022.951.
Sarosh Nagar joins Ethics Talk to discuss his article, coauthored with Drs Leah Z. Rand and Aaron S. Kesselheim: “What Should US Policymakers Learn From International Drug Pricing Transparency Strategies?”